Previous 10 | Next 10 |
WOODCLIFF LAKE, N.J., Aug. 22, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will present at the following healthcar...
2023-08-17 07:02:06 ET Eagle Pharmaceuticals Inc ( NASDAQ: EGRX ) Thursday reiterated its previously issued guidance for the 2023 fiscal year. Says full-year 2023 adjusted non-GAAP EBITDA is expected to range from $78.0 to $84.0 million and adjusted non-GAAP earnings per share...
-- FY 2023 Adjusted non-GAAP EBITDA expected to be $78.0 - $84.0 million 1 -- -- FY 2023 Adjusted non-GAAP earnings per share expected to be $4.40 - $4.70 1 -- -- Reflects strength of Eagle’s business and product pipeline; Company poised for sustained long-term growth -- WO...
2023-08-09 14:31:20 ET Piper Sandler has downgraded Eagle Pharmaceuticals ( NASDAQ: EGRX ) to underweight, citing concerns about the declining contribution of bendamustine products in the longer term. The investment bank said that Eagle was facing "challenging dynamics," includi...
2023-08-08 12:57:14 ET Eagle Pharmaceuticals, Inc. (EGRX) Q2 2023 Earnings Conference Call August 8, 2023, 08:30 AM ET Company Participants Lisa Wilson - IR Scott Tarriff - President and CEO Brian Cahill - CFO Conference Call Participants Tim Lugo - W...
2023-08-08 06:54:55 ET Eagle Pharmaceuticals press release ( NASDAQ: EGRX ): Q2 Non-GAAP EPS of $1.18 beats by $0.04 . Revenue of $64.6M (-12.8% Y/Y) beats by $5.24M . For further details see: Eagle Pharmaceuticals Non-GAAP EPS of $1.18 beats by $0.04, re...
• Total revenue for Q2 2023 was $64.6 million • Q2 2023 net income was $0.39 per basic and diluted share and adjusted non-GAAP net income 1 was $1.18 per basic and diluted share • Q2 2023 net income was $5.2 million • Q2 2023 adjusted non...
2023-08-07 14:31:02 ET Eagle Pharmaceuticals ( NASDAQ: EGRX ) is scheduled to announce Q2 earnings results on Tuesday, August 8th, before market open. The consensus EPS Estimate is $1.14 (-26.9% Y/Y) and the consensus Revenue Estimate is $59.36M (-19.9% Y/Y). Over the ...
2023-08-03 14:13:02 ET Summary Today, we are circling back on Eagle Pharmaceuticals for the first time in a while as the shares are down big since the start of 2022. The company is managing to stay profitable as it manages through a period of sales declines. Management did jus...
WOODCLIFF LAKE, N.J., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its second quarter 2023 financial results on Tuesday, August 8, 2023, before the market opens. ...
News, Short Squeeze, Breakout and More Instantly...
Eagle Pharmaceuticals Inc. Company Name:
EGRX Stock Symbol:
NASDAQ Market:
Eagle Pharmaceuticals Inc. Website:
2024-07-27 11:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-17 12:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-07 19:54:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...